Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Omalizumab, ATC L04AG08 für die Zeit 01.08.2026 - 31.07.2028
Opportunity Score
Confidence: 70%
Complexity: low
721 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
Non-exclusive discount agreement (Open House) for the active substance Omalizumab (ATC L04AG08) under §130a Abs.8 SGB V, concluded by DAK-Gesundheit for the period 01.08.2026 - 31.07.2028. The procedure allows any interested pharmaceutical company to join at any time by submitting required documents via email. The contract automatically ends when an exclusive contract for the same substance is concluded. Publication uses an open procedure form due to technical reasons; the procedure is not subject to procurement law.
Strengths
Documents available
Open procedure
Low complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Submit required documents via email to [email protected]
- Documents: Angebotsschreiben, signed contract, Anlagen 1 and 2
- Anlage 2 must be submitted as an Excel file
Buyer
Lots (1)
Open House for non-exclusive discount agreement on Omalizumab. All pharmaceutical companies may join at any time under identical conditions. Initial contracts start 01.08.2026, end 31.07.2028. Early termination upon conclusion of an exclusive contract. Submission is via email with specific documents.
Procurement Details
Publication
14 Jun 2026
Deadline
05 Jun 2028, 10:00
Procedure
open
Contract
supplies
Duration
24 MONTH
Language
DEU
Publication #
406825-2026
Classification
Performance: Germany
Documents (2)
Opportunity Score
Confidence: 70%
Complexity: low
721 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation